The state of Illinois currently has 4 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Primary Biliary Cholangitis, PBC
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Recruiting
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Springfield Clinic, Springfield, Illinois
Conditions: Primary Biliary Cholangitis
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
Recruiting
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/04/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Primary Biliary Cholangitis
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Recruiting
The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Northwestern University, Evanston, Illinois +1 locations
Conditions: Primary Biliary Cholangitis, Liver Stiffness